Cross-validation of optimized composites for preclinical Alzheimer's disease

INTRODUCTION: We discuss optimization and validation of composite end points for presymptomatic Alzheimer's disease clinical trials. Optimized composites offer hope of substantial gains in statistical power or reduction in sample size. But there is tradeoff between optimization and face validit...

Descripción completa

Detalles Bibliográficos
Autores principales: Donohue, Michael C., Sun, Chung-Kai, Raman, Rema, Insel, Philip S., Aisen, Paul S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527287/
https://www.ncbi.nlm.nih.gov/pubmed/28758145
http://dx.doi.org/10.1016/j.trci.2016.12.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527287/
https://www.ncbi.nlm.nih.gov/pubmed/28758145
http://dx.doi.org/10.1016/j.trci.2016.12.001

Ejemplares similares